| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $3,900,282 | 18 | 100 |
| Montgomery Alan Bruce | director | 0 | $0 | 1 | $62,338 | $-62,338 |
| GUSTAFSON KURT A | director | 0 | $0 | 1 | $67,385 | $-67,385 |
| RANIERI RICHARD J | director | 0 | $0 | 1 | $67,385 | $-67,385 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | 0 | $0 | 2 | $71,295 | $-71,295 |
| Eckert Celia | SVP, GENERAL COUNSEL | 0 | $0 | 3 | $73,700 | $-73,700 |
| Feigal Ellen | director | 0 | $0 | 1 | $89,370 | $-89,370 |
| GORMAN KEVIN CHARLES | director | 0 | $0 | 1 | $92,657 | $-92,657 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO | 0 | $0 | 4 | $1.26M | $-1.26M |
| Dahiyat Bassil I | PRESIDENT & CEO | 0 | $0 | 4 | $2.12M | $-2.12M |
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and …
Over the last 12 months, insiders at Xencor, Inc. have bought $0 and sold $3.9M worth of Xencor, Inc. stock.
On average, over the past 5 years, insiders at Xencor, Inc. have bought $1,013 and sold $2.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 53 shares for transaction amount of $1,013 was made by GORMAN KEVIN CHARLES (director) on 2024‑02‑13.
| 2026-06-18 | Sale | Feigal Ellen | director | 6,843 0.0095% | $13.06 | $89,370 | +88.92% | |
| 2026-06-15 | Sale | Montgomery Alan Bruce | director | 5,064 0.0069% | $12.31 | $62,338 | +94.72% | |
| 2026-06-15 | Sale | GUSTAFSON KURT A | director | 5,474 0.0074% | $12.31 | $67,385 | +94.72% | |
| 2026-06-15 | Sale | RANIERI RICHARD J | director | 5,474 0.0074% | $12.31 | $67,385 | +94.72% | |
| 2026-06-15 | Sale | GORMAN KEVIN CHARLES | director | 7,527 0.0102% | $12.31 | $92,657 | +94.72% | |
| 2026-04-10 | Sale | Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | 3,499 0.0047% | $12.29 | $42,990 | +57.25% | |
| 2026-03-06 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 6,606 0.0088% | $11.02 | $72,796 | +35.87% | |
| 2026-03-06 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 2,502 0.0033% | $11.02 | $27,571 | +35.87% | |
| 2026-03-06 | Sale | Eckert Celia | SVP, GENERAL COUNSEL | 1,767 0.0023% | $11.02 | $19,472 | +35.87% | |
| 2026-03-05 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 14,870 0.021% | $11.25 | $167,221 | +36.34% | |
| 2026-03-05 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 4,118 0.0058% | $11.25 | $46,309 | +36.34% | |
| 2026-03-05 | Sale | Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO | 2,517 0.0036% | $11.25 | $28,305 | +36.34% | |
| 2026-03-05 | Sale | Eckert Celia | SVP, GENERAL COUNSEL | 3,244 0.0046% | $11.25 | $36,480 | +36.34% | |
| 2026-03-03 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 6,758 0.0092% | $11.90 | $80,387 | +25.00% | |
| 2026-03-03 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 2,663 0.0036% | $11.90 | $31,677 | +25.00% | |
| 2026-03-03 | Sale | Eckert Celia | SVP, GENERAL COUNSEL | 1,492 0.002% | $11.90 | $17,747 | +25.00% | |
| 2025-12-19 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 114,377 0.1618% | $15.71 | $1.8M | -10.13% | |
| 2025-12-19 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 73,367 0.1039% | $15.72 | $1.15M | -10.13% | |
| 2025-06-16 | Sale | Montgomery Alan Bruce | director | 2,215 0.0032% | $9.22 | $20,422 | +32.93% | |
| 2025-06-16 | Sale | GUSTAFSON KURT A | director | 2,993 0.0043% | $9.22 | $27,595 | +32.93% |
| GORMAN KEVIN CHARLES | director | 11378 0.0153% | $348,621.92 | 1 | 3 | +10.67% |
| STAFFORD JOHN S JR | 10 percent owner | 2000443 2.6905% | $61.29M | 1 | 0 | +31.06% |
| STAFFORD JOHN S III | 10 percent owner | 606005 0.815% | $18.57M | 33 | 42 | +42.66% |
$21,345,882 | 83 | 94.45% | $2.19B | |
$52,263,649 | 70 | 1.18% | $2.49B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B | |
$586,486,795 | 47 | 4.28% | $2.38B |
| Increased Positions | 92 | +35.52% | 12M | +14.38% |
| Decreased Positions | 112 | -43.24% | 12M | -14.66% |
| New Positions | 34 | New | 3M | New |
| Sold Out Positions | 28 | Sold Out | 2M | Sold Out |
| Total Postitions | 239 | -7.72% | 82M | -0.29% |
| Blackrock, Inc. | $176,164.00 | 16.63% | 11.81M | -48,027 | -0.41% | 2025-09-30 |
| Primecap Management Co/Ca/ | $159,271.00 | 15.04% | 10.68M | +147,700 | +1.4% | 2025-09-30 |
| Vanguard Group Inc | $105,988.00 | 10.01% | 7.1M | -2M | -17.63% | 2025-09-30 |
| Rtw Investments, Lp | $92,818.00 | 8.76% | 6.22M | +4M | +158.9% | 2025-09-30 |
| Ecor1 Capital, Llc | $91,680.00 | 8.65% | 6.14M | 0 | 0% | 2025-09-30 |
| State Street Corp | $54,814.00 | 5.17% | 3.67M | -143,779 | -3.77% | 2025-09-30 |
| Bvf Inc/Il | $40,883.00 | 3.86% | 2.74M | 0 | 0% | 2025-09-30 |
| Tcg Crossover Management, Llc | $36,586.00 | 3.45% | 2.45M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $25,794.00 | 2.44% | 1.73M | +25,161 | +1.48% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $25,264.00 | 2.38% | 1.69M | -2M | -54.97% | 2025-09-30 |